Clinical Trial Update: Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics study of intravenous anidulafungin (Ecalta) in patients at high risk for invasive fungal disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Ecalta (anidulafungin)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED